Amylin Said to Draw $29-a-Share Offers in Initial Bidding

Amylin Pharmaceuticals Inc. is preparing for a second round of bids after attracting offers that value the diabetes drugmaker at $25 to $29 a share, said people with knowledge of the process.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.